BeesFree (BEES) 10-K 15 Apr 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 24, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'BeesFree, Inc.	'	'
Entity Central Index Key	'0001432139	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'BEES	'	'
Entity Common Stock, Shares Outstanding	'	16,344,728	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$1,593,350

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$153,542	$42,948
Prepaid expenses	56,588	97,541
Total Current Assets	210,130	140,489
Intangible assets	1,650	1,650
Deposit	3,125	3,125
Total Assets	214,905	145,264
Current Liabilities	'	'
Accounts payable	89,327	28,326
Accrued expenses	164,960	57,854
Share issuance liability	0	5,800
Accrued dividends on preferred stock	439,510	198,432
Derivative liabilities	1,248,943	730,174
Total Current Liabilities	1,942,740	1,020,586
Convertible note payable (net of debt discount of $334,209 as of December 31, 2013)	550,791	0
Total Liabilities	2,493,531	1,020,586
Commitments and Contingencies	'	'
Stockholders' Deficiency	'	'
Common stock, $0.001 par value; 200,000,000 shares authorized; 16,344,728 and 16,225,000 issued and outstanding as of December 31, 2013 and 2012, respectively	16,345	16,225
Additional paid-in-capital	2,127,556	2,059,872
Deficit accumulated during the development stage	-4,424,630	-2,953,622
Total Stockholders' Deficiency	-2,278,626	-875,322
Total Liabilities and Stockholders' Deficiency	214,905	145,264
Series A Preferred Stock [Member]	'	'
Stockholders' Deficiency	'	'
Preferred stock	2,100	2,200
Series B Preferred Stock [Member]	'	'
Stockholders' Deficiency	'	'
Preferred stock	$3	$3

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
			Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]
Convertible note payable (in dollars)	$334,209	'	'	'	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$1	$1	$175	$175
Preferred stock, shares authorized	5,000,000	5,000,000	3,500,000	3,500,000	50,000	50,000
Preferred stock, shares issued	'	'	2,100,000	2,200,000	3,099	3,099
Preferred stock, shares outstanding	'	'	2,100,000	2,200,000	3,099	3,099
Preferred stock, liquidation preference amount (in dollars)	'	'	$2,457,269	$2,383,812	$623,779	$556,945
Common stock, par value (in dollars per share)	$0.00	$0.00	'	'	'	'
Common stock, shares authorized	200,000,000	200,000,000	'	'	'	'
Common stock,shares issued	16,344,728	16,225,000	'	'	'	'
Common stock, shares outstanding	16,344,728	16,225,000	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended		29 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	$0	$0	$0
Operating Expenses	'	'	'
Research and development expenses	158,352	212,500	584,602
Merger expenses	0	0	415,000
General and administrative expenses	762,180	1,420,465	2,609,619
Total Operating Expenses	920,532	1,632,965	3,609,221
Change in fair value of derivative liabilities	-80,394	-66,501	-146,895
Interest expense	-219,276	0	-219,276
Net Loss	-1,220,202	-1,699,466	-3,975,392
Dividends to Preferred Stockholders	-250,806	-191,199	-449,238
Net Loss Attributable to Common Stockholders	($1,471,008)	($1,890,665)	($4,424,630)
Basic and Diluted Net Loss per Share (in dollars per share)	($0.09)	($0.12)	'
Weighted Average Number of Shares Outstanding - basic and diluted (in shares)	16,284,026	16,175,150	'

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
					Preferred Stock [Member]	Preferred Stock [Member]
Beginning Balance at Aug. 03, 2011	$0	$0	$0	$0	$0	$0
Beginning Balance (in shares) at Aug. 03, 2011	'	0	'	'	0	0
Issuance of Founders' shares August 22, 2011 (at $0.001 per share)	10,300	10,300	0	0	0	0
Issuance of Founders' shares August 22, 2011 (at $0.001 per share) (in shares)	'	10,300,000	'	'	0	0
Issuance of shares in exchange for patent -August 27, 2011 (at $0.001)	1,650	1,650	0	0	0	0
Issuance of shares in exchange for patent -August 27, 2011 (at $0.001) (in shares)	'	1,650,000	'	'	0	0
Issuance of shares pursuant to reverse recapitalization - December 16, 2011 (at $0.001)	0	4,000	-4,000	0	0	0
Issuance of shares pursuant to reverse recapitalization - December 16, 2011 (at $0.001) (in shares)	'	4,000,000	'	'	0	0
Issuance of preferred stock in private placement, net of costs	1,088,225	0	1,087,025	0	1,200	0
Issuance of preferred stock in private placement, net of costs (in shares)	'	0	'	'	1,200,000	0
Conversion of debentures into preferred stock - December 16, 2011 (at $1.00)	1,000,000	0	999,000	0	1,000	0
Conversion of debentures into preferred stock - December 16, 2011 (at $1.00) (in shares)	'	0	'	'	1,000,000	0
Issuance of shares to employee - December 30, 2011 (at $0.001)	200	200	0	0	0	0
Issuance of shares to employee - December 30, 2011 (at $0.001) (in shares)	'	200,000	'	'	0	0
Warrants issued in connection with convertible preferred stock or convertible note payable	-580,000	0	-580,000	0	0	0
Contractual dividends accrued on convertible preferred stock	-7,233	0	0	-7,233	0	0
Net loss	-1,055,724	0	0	-1,055,724	0	0
Ending Balance at Dec. 31, 2011	457,418	16,150	1,502,025	-1,062,957	2,200	0
Ending Balance (in shares) at Dec. 31, 2011	'	16,150,000	'	'	2,200,000	0
Issuance of shares pursuant to separation agreement (at $0.59)	23,600	40	23,560	0	0	0
Issuance of shares pursuant to separation agreement (at $0.59) (in shares)	'	40,000	'	'	0	0
Issuance of shares for services rendered	20,650	35	20,615	0	0	0
Issuance of shares for services rendered (in shares)	'	35,000	'	'	0	0
Issuance of preferred stock in private placement, net of costs	514,103	0	514,100	0	0	3
Issuance of preferred stock in private placement, net of costs (in shares)	'	0	'	'	0	3,099
Compensation expense associated with options	83,245	0	83,245	0	0	0
Warrants issued in connection with convertible preferred stock or convertible note payable	-83,673	0	-83,673	0	0	0
Contractual dividends accrued on convertible preferred stock	-191,199	0	0	-191,199	0	0
Net loss	-1,699,466	0	0	-1,699,466	0	0
Ending Balance at Dec. 31, 2012	-875,322	16,225	2,059,872	-2,953,622	2,200	3
Ending Balance (in shares) at Dec. 31, 2012	'	16,225,000	'	'	2,200,000	3,099
Issuance of shares for services rendered	5,800	10	5,790	0	0	0
Issuance of shares for services rendered (in shares)	'	10,000	'	'	0	0
Conversion of Series A pref stock (at $100) into common stock	9,728	110	9,718	0	-100	0
Conversion of Series A pref stock (at $100) into common stock (in shares)	'	109,728	'	'	-100,000	0
Compensation expense associated with options	5,626	0	5,626	0	0	0
Warrants issued in connection with convertible preferred stock or convertible note payable	46,550	0	46,550	0	0	0
Contractual dividends accrued on convertible preferred stock	-250,806	0	0	-250,806	0	0
Net loss	-1,220,202	0	0	-1,220,202	0	0
Ending Balance at Dec. 31, 2013	($2,278,626)	$16,345	$2,127,556	($4,424,630)	$2,100	$3
Ending Balance (in shares) at Dec. 31, 2013	'	16,344,728	'	'	2,100,000	3,099

CONSOLIDATED_STATEMENT_OF_CHAN1

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) (USD $)	5 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Common Stock [Member]	'	'	'
Common stock, founders' shares, par value	$0.00	'	'
Common stock, exchange for patent, par value	$0.00	'	'
Common stock, pursuant to reserve recapitalization, par value	$0.00	'	'
Common stock, issued to employee, par value	$0.00	'	'
Common stock, separation agreement, par value	'	'	$0.59
Common stock, for services, par value	'	$0.58	$0.59
Series A Preferred Stock [Member]	'	'	'
Preferred stock, private placement, par value	$1	'	'
Preferred stock, conversion of debentures, par value	$1	$100	'
Series B Preferred Stock [Member]	'	'	'
Preferred stock, private placement, par value	'	'	$175
Preferred stock, private placement net of costs	'	'	$28,222

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended		29 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash Flows from Operating Activities	'	'	'
Net loss	($1,220,202)	($1,699,466)	($3,975,392)
Adjustments to reconcile net income to net cash used in operating activities:	'	'	'
Amortization of deferred debt discount	150,716	0	150,716
Stock-based compensation	5,626	133,295	138,920
Change in fair value of derivative liabilities	80,394	66,501	146,895
Changes in operating assets and liabilities:	'	'	'
Deposits	0	-1,950	-3,125
Prepaid expenses	40,953	-87,041	-56,588
Accounts payable and accrued expenses	168,107	64,127	254,287
Total Adjustments	445,796	174,932	631,105
Net Cash Used in Operating Activities	-774,406	-1,524,534	-3,344,287
Net Cash From Investing Activities	0	0	0
Cash Provided by Financing Activities	'	'	'
Proceeds from issuance of convertible debentures	885,000	0	1,885,000
Proceeds from sale of convertible preferred stock, net of costs	0	514,103	1,714,104
Fees paid to third-parties in connection with sale of convertible preferred stock	0	0	-111,775
Proceeds from issuance of founders' common stock	0	0	10,300
Proceeds from sale of common stock	0	0	200
Net Cash Provided by Financing Activities	885,000	514,103	3,497,829
Net (Decrease) Increase in Cash	110,594	-1,010,431	153,542
Cash - Beginning	42,948	1,053,379	0
Cash - Ending	153,542	42,948	153,542
Non-Cash Investing and Financing Activities:	'	'	'
Conversion of convertible debentures into convertible preferred stock	0	0	1,000,000
Warrants issued in connection with convertible preferred stock	0	83,673	663,673
Conversion of accrued dividends into common stock	9,728	0	9,728
Warrants issued in connection with convertible notes payable	477,050	0	477,050
Fair value of conversion option issued in connection with convertible note payable	7,875	0	7,875
Dividends accrued on convertible preferred stock	250,806	191,199	449,238
Settlement of share issuance liability	5,800	0	5,800
Shares issued relating to merger recapitalization	0	0	4,000
Shares issued related to acquisition of intangible asset	$0	$0	$1,650

BUSINESS_ORGANIZATION_AND_NATU

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	'
	Note 1 - Business  Organization and Nature of Operations
	BeesFree, Inc. was incorporated on September 4, 2007 in the State of Nevada. BeesFree, Inc. (collectively with its subsidiaries, “BeesFree” or the “Company”) and  is a development stage company which has developed a proprietary composite food supplement for honeybees, BeesVita PlusTM, that it believes prevents the effects of colony collapse disorder (“CCD”). CCD is a phenomenon in which worker bees from a beehive or colony abruptly disappear effectively killing the colony. The Company’s goal is to initially sell products directly to large beekeepers in the United States, Europe and Argentina.
	The Company has been presented as a "development stage enterprise”. The Company’s primary activities since inception have been developing its technology, developing its business plan, filing patents, complying with the regulatory requirements to sell its product in various countries, developing an infrastructure to sell and deliver its product, and raising capital. The Company has not commenced principal operations of selling its product, nor has it generated any revenues from operations.
	The Company has commenced business development activities in Argentina, Italy and the United States and begun a program of brand awareness. The Company is based in West Palm Beach, Florida, and has operations in Rome, Italy and Buenos Aires, Argentina.

GOING_CONCERN_AND_MANAGEMENT_P

GOING CONCERN AND MANAGEMENT PLANS	12 Months Ended
	Dec. 31, 2013
Going Concern Disclosure [Abstract]	'
Going Concern Disclosure [Text Block]	'
	Note 2 - Going Concern and Management Plans
	The Company is currently in the development stage, has not yet generated any revenues since inception.  As of December 31, 2013, the Company had a working capital deficiency of $1,732,610 and a stockholders’ deficiency of $2,278,626.  The Company has incurred net losses of $3,975,392 during the period from August 4, 2011 (inception) through December 31, 2013.  The Company believes that its current cash on hand may be insufficient to fund its projected operating requirements into the second quarter of 2014. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company's primary source of operating funds since inception has been cash proceeds from the sale of convertible debentures and the sale of preferred stock and warrants in private placements. The Company intends to raise additional capital through private debt and equity investors, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.
	Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business.  The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.  The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 3 - Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of BeesFree, Inc. and its subsidiaries. All significant intercompany transactions have been eliminated in the consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation,  derivative liabilities and the valuation allowance relating to the Company’s deferred tax assets.
	Concentrations of Credit Risk
	The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2013 and 2012, the Company does not have any cash equivalents.
	Income Taxes
	Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.  The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of these differences that have been included or excluded in the financial statements or tax returns.
	The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 740 “Income Taxes”, which prescribes a recognition threshold and measurement process for consolidated financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also prescribes direction on the recognition, classification, interest and penalties in interim periods, disclosure and transition.
	The Company classifies interest expense and any related penalties, if any, related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized as of December 31, 2013 and 2012.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements for the period from August 4, 2011 (inception) through December 31, 2013.  The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date.
	Preferred Stock
	Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, the Company classifies its preferred shares in stockholders’ equity. As of December 31, 2013 and 2012, the Company’s preferred shares do not feature any redemption rights within the holders’ control or conditional redemption features not within the Company’s control.  Accordingly, all issuances of preferred stock are presented as a component of consolidated stockholders’ (deficiency) equity.
	Convertible Instruments
	The Company bifurcates conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule when the host instrument is deemed to be conventional as that term is described under applicable U.S. GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.  Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock.  The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its private placement transactions (see Note 6). The Company evaluated these warrants to assess their proper classification in the balance sheet as of December 31, 2013 and 2012 using the applicable classification criteria enumerated under U.S. GAAP. The Company determined that the common stock purchase warrants do not contain fixed settlement provisions because the exercise price is subject to adjustment in the event that the Company subsequently issues equity securities or equity linked securities with exercise prices lower than the exercise price in these warrants.
	As such, the Company was required to record the warrants which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.
	Research and Development
	Research and development (“R&D”) expenses are charged to operations as incurred. During the years ended December 31, 2013 and 2012,   and the period from August 4, 2011 (inception) to December 31, 2013, the Company incurred R&D expenses of $158,352, $212,500 and $584,602, respectively.
	Net Loss Per Share
	The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2013 and 2012 excludes potentially dilutive securities because their inclusion would be anti-dilutive. Anti-dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:
		December 31,
		2013		2012
	Warrants to purchase common stock	10,429,900		2,629,000
	Options to purchase common stock	812,500		2,000,000
	Shares issuable upon conversion of convertible notes and accrued interest	953,560		-
	Series A Convertible Preferred Stock	2,457,269		2,200,000
	Series B Convertible Preferred Stock	623,779		309,900
	Totals	15,277,008		7,139,800
	Share-based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and amortized over the respective employment agreements or director service periods. For non-employees, the fair value of the award is measured on the commitment date and generally remeasured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations as if such amounts were paid in cash.
	Fair Value of Financial Instruments
	The carrying amounts of cash, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	Financial liabilities as of December 31, 2013 and 2012 measured at fair value on a recurring basis are summarized below:
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2013			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	1,248,943		$	—	$	—	$	1,248,943
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2012			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	730,174		$	—	$	—	$	730,174
	The Company determined that the warrants issued in connection with certain Preferred Stock financing transactions and the conversion option and warrants related to certain convertible notes (See Note 5) did not have fixed settlement provisions and are deemed to be derivative financial instruments, since the exercise prices were subject to adjustment based on certain subsequent equity issuances.  Accordingly, the Company was required to record the warrants and conversion option as liabilities and mark to market all such derivatives to fair value each reporting period. Such instruments were classified within Level 3 of the valuation hierarchy.
	Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the warrant liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s Chief Financial Officer, who reports to the Chief Executive Officer, determine its valuation policies and procedures.
	The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.
	Level 3 financial liabilities consist of the warrant liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation.  Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
	The fair value of the Company’s warrant liabilities is estimated using a compound option model that includes characteristics of both a binomial lattice and the Black-Scholes valuation model (see Note 6). Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. Changes in the values of the derivative liabilities are recorded in Change in Fair Value of Warrants on the Company’s consolidated statements of operations. From August 4, 2011 (inception) to December 31, 2013, there were no transfers between levels in the fair value hierarchy.
	The risk-free interest rate is the United States Treasury rate for the day of the grant having a term equal to the contractual life of the warrant. An increase in the risk-free interest rate will increase the fair value and the related change in fair value.  The volatility is a measure of the amount by which the Company’s share price has fluctuated or is expected to fluctuate. Since the Company’s common stock has not been publicly traded for a long period of time, an average of the historic volatility of comparative companies was used.  The dividend yield is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future.
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis for the years ended December 31, 2013 and 2012:
	2013			2012
Balance - Beginning of period	$	730,174		$	580,000
Derivative instruments issued		438,375			83,673
Change in fair value of derivative liabilities		80,394			66,501
Balance - End of period	$	1,248,943		$	730,174
Recent Accounting Pronouncements
The Financial Accounting Standards Board (“FASB”) has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
Subsequent Events
Management has evaluated subsequent events or transactions occurring through the date on which the consolidated financial statements were issued.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 4 - Income Taxes
	The tax effects of temporary differences that give rise to deferred tax assets as of December 31, 2013 and December 31, 2012 are presented below:
		2013		2012
	Deferred Tax Assets:
	Net operating loss carryforward	$	1,247,206	$	941,555
	Stock based compensation		50,500		—
	Total Deferred Tax Asset		1,297,706		941,555
	Valuation allowance		-1,297,706		-941,555
	Deferred Tax Asset, Net of Valuation Allowance	$	—	$	—
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2013 and 2012 is as follows:
		2013		2012
	U.S. federal statutory rate	-34	%	-34	%
	State and local tax, net of federal benefit	-2.4	%	-3.6	%
	Change in fair value of derivative liability and other permanent differences	7.2	%	-3.4	%
	Change in valuation allowance	29.2	%	41	%
	Income tax provision (benefit)	0	%	0	%
	The income tax provision (benefit) for the year ended December 31, 2013 and 2012 consists of the following:
		2013		2012
	Federal
	Current	$	—	$	—
	Deferred		-333,108		-851,406
	State and Local
	Current		-		-
	Deferred		-23,043		-90,149
	Valuation Allowance		356,151		941,155
	Income Tax Provision (Benefit)	$	—	$	—
	The Company files its income tax returns in the U.S. federal jurisdiction and the state of Florida. The Company’s federal and state income tax returns are subject to examination by tax authorities beginning with the year ended December 31, 2010.
	At December 31, 2013 and 2012, the Company had approximately $3,431,000 and $2,298,000 of federal and state net operating losses that may be available to offset future taxable income. The net operating loss carryforwards will begin to expire in 2027 unless utilized. In accordance with Section 382 of the Internal Revenue Code, deductibility of the Company’s U.S. net operating carryovers may be subject to an annual limitation in the event of a change of control as defined the regulations. Based upon a preliminary evaluation, management has determined that $802,671 of the Company’s net operating loss carryovers are subject to an annual limitation under Section 382.
	The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established.  Based upon the Company’s losses since inception, management believes that it is more likely than not that the future benefits of its deferred tax assets will not be realized and has therefore established a full valuation allowance. As of December 31, 2013 and December 31, 2012, the change in valuation allowance was $356,157 and $941,155, respectively.

SENIOR_SECURED_CONVERTIBLE_NOT

SENIOR SECURED CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 5 – Senior Secured Convertible Note s
	On March 13, 2013, (the “Initial Closing Date’), in connection with its offering of Senior Secured Convertible Notes (the “Notes”) the Company entered into a securities purchase agreement (the “Purchase Agreement”) and issued a Note to one investor in the principal amount of $210,000.  The Notes are collateralized by all of the assets of the Company and bear interest at a rate of 15% per annum, compounded quarterly. Principal and accrued interest on the Notes are convertible into shares of the Company’s common stock at an initial conversion price of $1.50 per share (the “Initial Conversion Price”). Principal and accrued interest on the Notes are due and payable twenty-four (24) months from the date of the Purchase Agreement (the “Maturity Date”). The investor also initially received a warrant exercisable for a period of five years from issuance to purchase 1,400,000 shares of the Company’s common stock (the “Warrant Shares”) at an initial exercise price of $1.50 per share. The warrant contains certain cashless exercise provisions.  The Note and Warrant Shares are subject to certain registration rights.  Subsequent to the Initial Closing Date, the Company revised the terms of the Note offering to increase the number of warrants to 1,050,000 per $105,000 invested, and issued an additional 700,000 warrants to the investor. As a result of issuing the additional warrants, for the year ended December 31, 2013, the Company recorded a charge of $35,000 related to the modification of the note.
	Between June 20, 2013 and June 24, 2013, the Company sold additional Notes and entered into and consummated an Amended and Restated Securities Purchase Agreement, with two accredited investors, whereby the Company sold additional Notes in the aggregate principal amount of $525,000. The investors also received warrants exercisable for a period of five years from issuance to purchase an aggregate of 5,250,000 Warrant Shares at an initial exercise price of $1.50 per share.
	The Initial Conversion Price and the initial exercise price of the Warrant Shares are subject to full-ratchet price protection in the event that the Company issues or sells, or is deemed to have issued or sold, subject to certain standard exceptions, any shares of its common stock or securities convertible into common stock for consideration per share less than the Initial Conversion Price. As such, the Company determined that the conversion option and warrants, as originally issued, did not contain fixed settlement provisions due to price protection adjustments based on certain subsequent equity issuances. As such, the Company was required to record the conversion option and warrants as derivative liabilities and mark to market all such derivatives to fair value each reporting period through December 31, 2013.
	On December 31, 2013, the Company sold additional convertible promissory notes (the “December 2013 Notes) to two accredited investors in the aggregate principal amount of $150,000 pursuant to a new round of convertible debt financing and the Company  entered into a Securities Purchase Agreement with such investors (the “December Purchase Agreement”). The December 2013 Notes are collateralized by all of the assets of the Company and bear interest at a rate of 15% per annum, compounded quarterly. Principal and accrued interest on the December 2013 Notes are convertible into shares of the Company’s common stock at an initial conversion price of $1.00 per share. Principal and accrued interest on the Notes are due and payable twenty-four (24) months from the date of the December Purchase Agreement. The investors also initially received warrants exercisable for a period of five years from issuance to purchase an aggregte of 450,000 shares of the Company’s common stock (the “December Warrant Shares”) at an initial exercise price of $1.00 per share. The warrant contains certain cashless exercise provisions. The December 2013 Notes and December Warrant Shares are subject to certain registration rights. As a result of the December Warrant Shares being issued at an initial exercise price of $1.00 per share, the exercise price of the Warrant Shares issued in March 2013 under the “Purchase Agreement” and the Warrant Shares issued in June 2013 under the Amended and Restated Securities Purchase Agreement adjusted from $1.50 per share to $1.00 per share due to full-ratchet price protection provision.
	The cumulative gross proceeds of the Notes and December 2013 Notes in the amount of $885,000  for the year  ending December 31, 2013. The Notes were recorded net of a debt discount of $438,375. The debt discount consisted of $430,500 related to the fair value of the warrants and $7,875 related to the fair value of the embedded conversion option. The warrants and conversion option were valued using a compound option model that includes characteristics of both a binomial lattice and the Black-Scholes formula and measured at fair value on a recurring basis through December 31, 2013 (See Note 3). The cumulative gross proceeds of the December 2013 Notes which aggregated $150,000 were recorded net of a discount of $46,550 relating to the relative fair value of the December Warrant Shares. The aggregate  debt discount of $484,925 is being accreted over the term of the notes. Accordingly, the Company recorded a charge of $150,716 to interest expense for the year ended December 31, 2013.

STOCKHOLDERS_DEFICIENCY

STOCKHOLDERS' DEFICIENCY	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6 – Stockholders’ Deficiency
	Authorized Capital
	The Company is authorized to issue 200,000,000 shares of common stock with a $0.001 par value and 5,000,000 shares of preferred stock with a $0.001 par value, of which 3,500,000 shares have been designated as Series A Cumulative Convertible Preferred Stock and 50,000 shares have been designated as Series B Cumulative Convertible Preferred Stock.  The holders of the Company’s common stock are entitled to one vote per share.  Subject to the rights of holders of preferred stock, if any, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Subject to the rights of holders of preferred stock, if any, upon liquidation, dissolution or winding down of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available for distribution.
	Preferred Stock
	Series A Preferred Stock
	Each share of Series A Preferred Stock will accrue cumulative dividends at a rate of 8% per annum. All dividends will be paid in shares of common stock having a fair market value at the time of issuance equal to the amount of dividends to be paid. Such dividends shall compound annually and be fully cumulative, and shall accumulate from the date of original issuance of the Series A Preferred Stock until paid. As of December 31, 2013 and 2012, accrued dividends for the Series A Preferred Stock was $358,056 and $183,812, respectively.
	Upon any liquidation of the Company, the holders of the Series A Preferred Stock will be entitled to be paid, prior to the common stock or any other securities that by their terms are junior to the Series A Preferred Stock, the original issue price of the Series A Preferred Stock, plus all accrued and unpaid dividends. To the extent the proceeds of liquidation are insufficient to pay such amounts in full, the proceeds available will be allocated pro-rata among the shares of Series A Preferred Stock. As of December 31, 2013, the liquidation value of the Series A Preferred Stock was $2,457,269.
	Series B Preferred Stock
	On October 10, 2012, the Company sold 3,099 shares of its Series B Cumulative Convertible Preferred Stock (the “Series B Preferred Stock”) and five-year common stock purchase warrants to purchase 309,900 shares of the Company’s common stock at an initial exercise price of $2.62 per share (the “Series B Warrants”) in a private placement to accredited investors (the “October 2012 Private Placement”) for aggregate cash proceeds of $542,325.
	At any time prior to the third anniversary of the initial date of issuance, any holder of the Series B Preferred Stock may convert all or a portion of their shares into shares of the Company’s common stock.  The conversion price of each share of Series B Preferred Stock is equal to the sum of the “stated value” of the Series B Preferred Stock being converted ($175.00) divided by the conversion price then in effect (initially $1.75 per share, currently $1.00 per share).  Upon the third anniversary of the date of issuance, each share of Series B Preferred Stock still outstanding, unless there is an event of default (as defined), will automatically convert into shares of Common Stock at the then effective conversion ratio.
	The “conversion price” of the Series B Preferred Stock is subject to adjustment upon the occurrence of certain events, including, among others, a stock split, reverse stock split, stock dividend or combination of the Company's common stock, as well as certain protection for subsequent issuances of convertible or equity securities at prices more favorable than the stipulated conversion price.   Since the host Convertible Preferred instrument is deemed to be an equity instrument, the conversion option is considered have economic characteristics and risks that are clearly and closely related to the host contract and the embedded conversion option has not been bifurcated from the host instrument.
	The exercise price of the Series B Warrants is subject to adjustment upon the occurrence of certain events, including, among others, a stock split, reverse stock split, stock dividend or combination of the Company's common stock, as well as certain protection for subsequent issuances of equity securities at prices more favorable than the stipulated exercise price.
	The Company determined that the warrants, as originally issued, did not contain fixed settlement provisions because the exercise price was subject to adjustment based on certain subsequent equity issuances. As such, the Company was required to record the warrants which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value each reporting period through December 31, 2013.
	The Company valued  the Series B Warrants issued in connection with the Private Placement and accordingly, recorded a $83,673 liability relating to the fair value of the warrants on the date of issuance.  The fair value of these warrants on the issuance date was calculated using a compound option model that includes characteristics of both a binomial lattice and the Black-Scholes formula with the following weighted average assumptions:
	Dividend Yield		0	%
	Volatility		95	%
	Risk-free Interest Rate		0.66-0.72	%
	Expected Lives		4.78 years
	Weighted Average Fair Value per Warrant		0.25	%
	Warrants Issued		309,900
	Aggregate Grant Date Fair Value	$	83,673
	Each share of Series B Preferred Stock will accrue, on a pari passu basis with holders of the Series A Preferred Stock,  cumulative dividends at a rate of 12% per annum. All dividends will be paid in shares of common stock having a fair market value at the time of issuance equal to the amount of dividends to be paid. Such dividends shall compound annually and be fully cumulative, and shall accumulate from the date of original issuance of the Series B Preferred Stock until paid. As of December 31, 2013 and 2012, accrued dividends for the Series B Preferred Stock was $81,454, and $14,620, respectively.
	Upon any liquidation of the Company, the holders of the Series B Preferred Stock will be entitled to be paid on a pari passu basis with holders of the Series A Preferred Stock, prior to the common stock or any other securities that by their terms are junior to the Series B Preferred Stock, the original issue price of the Series B Preferred Stock, plus all accrued and unpaid dividends. To the extent the proceeds of liquidation are insufficient to pay such amounts in full, the proceeds available will be allocated pro-rata among the shares of Series B Preferred Stock on a pari passu basis with holders of the Series A Preferred Stock. As of December 31, 2013, the liquidation value of the Series B Preferred Stock was $623,779.
	During the year ended December 31, 2013, the Company issued Senior Secured Convertible Notes with an initial conversion price of $1.00 per share (see Note 5). Due to certain ratchet provisions relating to the Company’s Series B Convertible Preferred Stock, the Company reduced the per share conversion price of certain previously issued shares of Series B Convertible Preferred Stock from $1.75 to $1.00. As of December 31, 2013, the Company’s issued and outstanding shares of Series B Convertible Preferred Stock are convertible into 542,325 shares of common stock. In addition, as of December 31, 2013, the Company recorded accrued dividends convertible into 81,454 shares of common stock resulting in an aggregate of 623,779 shares of common stock. Since the Company’s Certificate of Designations setting for the relative rights and preferences of the Series B Convertible Preferred Stock (the “Certificate of Designations”) was deemed to be an equity instrument, the conversion option was considered to have economic characteristics and risks that are clearly and closely related to the Certificate of Designations and the embedded conversion option was not bifurcated from the Certificate of Designations.
	In connection with the Series B Preferred Stock, the Company incurred costs with third-parties of approximately $28,222, which were netted against the proceeds received.
	Common Stock
	In August 2012, the Company entered into a six-month agreement with a consultant to provide investor relations services.  Pursuant to the agreement the Company agreed to issue 35,000 common stock shares as part of the compensation to the consultant.    As of December 31, 2013, the Company recorded an expense relating to the shares of $20,650 as General and Administrative Expenses in the accompanying consolidated statement of operations.
	In October 2012, the Company entered into an agreement with a consultant to provide investor relations services.  Pursuant to the agreement the Company agreed to issue 10,000 common stock shares as part of the compensation to the consultant.    During the year ended December 31, 2012, the Company recorded an expense relating to the shares of $5,800 as General and Administrative Expenses in the accompanying consolidated statement of operations.
	In July 2013, pursuant to the terms of the Company’s Series A Cumulative Convertible Preferred Stock, the Company issued 109,728 shares of common stock as the result of a conversion of 100,000 shares of Series A Cumulative Convertible Preferred Stock, and accumulated dividends of $9,728.
	Options
	In April 2012, the Company granted to certain Directors options to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $2.30 per share, of which 50,000 options vested on the date of grant and 50,000 options shall vest on the first anniversary of the date of grant, provided such directors are currently serving as board members on such date. The options shall expire on the fourth anniversary of the applicable vesting date. The fair value of these options is $1,190 based on the Black-Scholes option pricing model.
	In June 2012, the Company granted to a Director, an option to purchase 50,000 shares of the Company’s common stock at an exercise price of $1.97 per share, of which 25,000 options vested on the date of grant and 25,000 options shall vest on the first anniversary of the date of grant, provided such director is currently serving as a board member on such date.
	The options shall expire on the fourth anniversary of the applicable vesting date. The fair value of this option is $905 based on the Black-Scholes option pricing model.
	In August 2012, the Company granted to a Director, an option to purchase 50,000 shares of the Company’s common stock at an exercise price of $1.88 per share, of which 25,000 options vested on the date of grant and 25,000 options shall vest on the first anniversary of the date of grant, provided such director is currently serving as a board member on such date. The options shall expire on the fourth anniversary of the applicable vesting date. The fair value of this option is $1,022 based on the Black-Scholes option pricing model.
	In August 2012, the Company granted to certain Advisory Board Members, options to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $1.82 per share, of which 50,000 options vested on the date of grant and 50,000 options shall vest on the first anniversary of the date of grant, provided such Advisory Board Members are currently serving as board advisory members on such date. The options shall expire on the fourth anniversary of the applicable vesting date. The fair value of these options is $7,587 based on the Black-Scholes option pricing model.
	In October 2012, as part of an employment agreement entered into with the Company’s President, Chief Executive Officer and Chief Financial Officer (see Note 7),  the Company issued stock options to purchase an aggregate of 1,700,000 shares of the Company’s common stock at an exercise price of $1.55 per share, which was the closing sale price of the Company’s common stock on the date the agreement was executed; 250,000 of such options were fully vested upon execution of the agreement, 250,000 options vested on December 31, 2012 and the remaining options were to vest based upon the Company meeting certain Performance Measurements as defined in the agreement. Each option is exercisable for a period of four years from the date of vesting of the options.  The fair value of the vested options not subject to performance criteria are $76,392 based on the Black-Scholes option pricing model.
	During the year ended December 31, 2013, the Company granted an aggregate of 75,000 options to purchase common stock to certain directors with exercise prices between $0.11 and $0.52 per share. The options have a 5 year term, vest on the one-year  anniversary of the date of grant if such individual continues to serve as a director of the Company on such date and have an aggregate grant date fair value of $5,310 based on the Black-Scholes option pricing model.
	As of December 31, 2013, stock options to purchase an aggregate of 1,262,500  shares of the Company’s common stock were forfeited by a former executive officer and certain directors and advisory board members as the result of their resignations.
	The Company recorded $5,625, $133,295 and $138,920 of stock based compensation expense for the years ended December 31, 2013 and 2012, and for the period from August 4, 2011 (Inception) to December 31, 2013, respectively.
	As of December 31, 2013, there was $1,550 of total unrecognized compensation expense related to unvested employee stock options not subject to performance criteria.  This expense is expected to be recognized over a remaining weighted-average period of approximately 0.5 year.
	The Company has computed the fair value of options granted using the Black-Scholes option pricing model. Forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The expected term of options granted represents the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” option grants. Since the Company’s stock has not been publicly traded for a long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of these options, of similarly positioned public companies within its industry. The Company estimated forfeitures related to option grants at an annual rate of 0% per year for options granted during the years ended December 31, 2013 and 2012. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the options.
	The following assumptions were used in estimating the fair value of stock options granted during the years ended December 31, 2013 and 2012:
		2013				2012
	Weighted Average Exercise Price	$	0.37			$	1.62
	Expected Life		2 years				2-5 years
	Volatility		125	%			50	%
	Dividend Yield		0	%			0	%
	Risk-free interest rate		0.30% - 1.62	%			0.41	%
	Weighted Average Grant Date Fair Value of Options Issued	$	0.37			$	1.7
	A summary of the Company’s options outstanding and exercisable is presented below:
						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
		Number of		Exercise		Life		Intrinsic
		Shares		Price		(Years)		Value
	Balance – January 1, 2012	-		-		-
	Granted	2,000,000		1.62		5.18
	Exercised	-
	Cancelled	-
	Balance – December 31, 2012	2,000,000		1.62		5.18		$	—
	Granted	75,000		0.37		4.48
	Exercised	-
Cancelled	1,262,500		1.57		-
Balance – December 31, 2013	812,500		1.58		3.04		$	—
Balance – December 31, 2013 (exercisable)	737,500		1.7		2.89		$	—
Options outstanding at December 31, 2013 have an exercise price of $0.11 to $2.30 per share.
Warrants
The following table summarizes the Company’s warrant activity through December 31, 2013:
						Weighted
						Average
			Weighted			Remaining
			Average			Contractual		Aggregate
	Number of		Exercise			Life		Intrinsic
	Shares		Price			(Years)		Value
Warrants outstanding at January 1, 2012	2,320,000		$	1		2.96
Granted	309,900		$	1		3.78
Warrants outstanding at December 31, 2012	2,629,900		$	1		3.06
Granted	7,800,000		$	1		4.43
Expired	—			—		—
Exercised	—			—		—
Warrants outstanding at December 31, 2013	10,429,900		$	1		4.08		$	—
Warrants outstanding at December 31, 2013 (exercisable)	10,429,900		$	1		4.08		$	—

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 7 - Commitments and Contingencies
	Litigations, Claims and Assessments
	In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the consolidated financial statements as of December 31, 2013 and 2012.
	Operating Leases
	On April 24, 2013, the Company entered into a commercial lease agreement in West Palm Beach, Florida under a one year operating lease that commenced on June 1, 2013 at the rate of $1,020 per month.    This lease agreement superceded a previous six month operating lease that commenced on December 1, 2012 at the rate of $975 per month.
	On May 25, 2012, the Company entered into a commercial lease agreement in Rome, Italy under a one-year operating lease that commenced on June 1, 2012 at the rate of approximately $1,300 per month. In May 2013, the lease agreement was extended for an additional year at the same terms.
	Aggregate rent expense for the years ended December 31, 2013 and 2012 was $29,344 and $9,180, respectively.  Aggregate rent expense for the period from August 4, 2011 (inception) to December 31, 2013 was $38,524.  As of December 31, 2013, future minimum rental payments on the Company’s operating leases aggregated approximately $10,300.
	Employment and Separation Agreements
	In June 2012, the Company entered into a Separation and General Release Agreement with its President, Chief Executive Officer and Director (the “Officer”). Pursuant to the agreement the Company paid the Officer a one-time cash payment of $21,513, representing amounts due under the Officer’s employment agreement and the reimbursement of certain expenses.  The Company also issued the Officer 40,000 shares of the Company’s restricted common stock valued at $23,600, based on the fair value of the shares on the date of the agreement.
	On October 19, 2012, the Company announced that David W. Todhunter was appointed as the Company’s President and Chief Executive Officer in addition to being the Company’s Chief Financial Officer and entered into a new employment agreement (the “Agreement”). The Agreement was to initially expire on December 31, 2015.  Under the terms of the Agreement, Mr. Todhunter was to receive an initial annual base salary of $126,000 until March 31, 2013 with future salary adjustments subject to certain terms and conditions.  In addition, Mr. Todhunter was to be entitled to receive on a fiscal year basis a cash bonus determined in the discretion of the Board of Directors of up to fifty (50%) percent of his annual salary. Upon execution of the Agreement, Mr. Todhunter was also issued certain stock options (See Note 6).
	management changes
	On April 15, 2013, David W. Todhunter resigned as President, Chief Executive Officer and Chief Financial Officer of the Company.  Subsequently, the Company announced that Juan Carlos Trabucco, a director of the Company, was appointed to serve as interim President and Chief Executive Officer and that Joseph N. Fasciglione, the Controller, Assistant Treasurer and Assistant Secretary of the Company, was appointed to serve as interim Chief Financial Officer.
	On April 17, 2013, Joseph Becker resigned as a director of the Company.
	On May 13, 2013, Juan Carlos Trabucco, a director and the Interim President and Chief Executive Officer of the Company, passed away.  Subsequently,  the Company appointed Joseph N. Fasciglione, the Company’s Interim Chief Financial Officer, to serve as Interim President and Chief Executive Officer of the Company pending the Company’s selection of a successor to serve as President and Chief Executive Officer.
	On November 6, 2012, the Company entered into a three-year consulting service agreement with Dr. Francesca del Vecchio, pursuant to which Dr. del Vecchio will continue to lead and manage all research and development activities in connection with the Company’s BeesVita Plus™ and other products.   During the first year of the Consulting Agreement, Dr. del Vecchio will be paid $7,750 per month.  Dr. del Vecchio’s compensation for the two remaining years of the Consulting Agreement will be determined by the mutual consent of the Company and Dr. del Vecchio.  Dr. del Vecchio is the spouse of the Chairman of the Company’s Board of Directors.
	On February 12, 2013, pursuant to terms of consulting agreement, the Company issued 10,000 shares of of common stock as part of compensation for services rendered.  The fair value of the shares issued was $5,800, based on the fair value of the shares on the date of the date issued
	Agreements
	On August 2, 2013, the Company entered into a manufacturing agreement with a domestic agricultutral specialty products company for the production of the Bees Vita Plus supplement to be sold in the U.S. market. The agreement is cancelable at any time by either party with a 30 days notice.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 8 – Subsequent events
	On February 12, 2014, the Company announced that Steven Elliott was appointed as the Company’s President and Chief Executive Officer and entered into an employment agreement (the “Elliott Agreement”). The Elliott Agreement will initially expire on February 12, 2018. Under the terms of the Elliott Agreement, Mr. Elliott will receive an annual base salary of $240,000 subject to certain terms and conditions. In addition, Mr. Elliott will be entitled to receive on a fiscal year basis a cash bonus determined in the discretion of the Board of Directors of up to fifty (50%) percent of his annual salary. Under the terms of the Elliott Agreement, Mr. Elliott was issued stock options to purchase an aggregate of 3,000,000 shares of the Company’s common stock at an exercise price of $0.50 per share which shall vest as follows (i) 750,000 of such options shall vest upon consummation of a debt or equity financing, or combination thereof, of not less than $3,000,000, (ii) 562,500 options shall vest on the first anniversary of the date of the Elliott Agreement and (iii) the remaining 1,687,500 options shall vest monthly in equal monthly amounts of 46,875 options per month, for each of the 36 months following the first anniversary of the date of the Elliott Agreement.
	On April 8, 2014, Steven Elliott resigned as President and Chief Executive Officer of the Company. Subsequently the Company appointed Joseph N. Fasciglione, the interim Chief Financial Officer, to serve as interim President and interim Chief Executive Officer.
	On February 12, 2014, the Company entered into a four-year consulting service agreement (the “Consulting Agreement”) with Dr. Andrea Festuccia, PhD. (“Consultant”), pursuant to which Dr. Festuccia will serve as Chief Strategist in enhancing product value, competitiveness and performance for the Company. In consideration for the services to be provided, the Company shall pay Consultant a consulting fee of $240,000 per year payable at a rate of $20,000 per month. Dr. Festuccia is also Chairman of the Company’s Board of Directors.
	Between February 14, 2014 and March 7, 2014, the Company has completed the sale of additional December 2013 Notes to two investors who became parties to the December Purchase Agreement. Such investors each invested the principal amount of $100,000. The investors also received warrants exercisable for a period of five years from issuance to purchase an aggregate of 600,000 December Warrant Shares at an initial exercise price of $1.00 per share. The warrant contains certain cashless exercise provisions and the shares of Common Stock underlying the December 2013 Notes and Warrant Shares are subject to certain registration rights

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
PRINCIPLES OF CONSOLIDATION [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of BeesFree, Inc. and its subsidiaries. All significant intercompany transactions have been eliminated in the consolidation.
USE OF ESTIMATES [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation,  derivative liabilities and the valuation allowance relating to the Company’s deferred tax assets.
CONCENTRATIONS OF CREDIT RISK [Policy Text Block]	'
	Concentrations of Credit Risk
	The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC
CASH AND CASH EQUIVALENTS [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2013 and 2012, the Company does not have any cash equivalents.
INCOME TAXES [Policy Text Block]	'
	Income Taxes
	Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.  The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of these differences that have been included or excluded in the financial statements or tax returns.
	The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 740 “Income Taxes”, which prescribes a recognition threshold and measurement process for consolidated financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance also prescribes direction on the recognition, classification, interest and penalties in interim periods, disclosure and transition.
	The Company classifies interest expense and any related penalties, if any, related to income tax uncertainties as a component of income tax expense. No interest or penalties have been recognized as of December 31, 2013 and 2012.
	Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements for the period from August 4, 2011 (inception) through December 31, 2013.  The Company does not expect any significant changes in the unrecognized tax benefits within twelve months of the reporting date.
PREFERRED STOK [Policy Text Block]	'
	Preferred Stock
	Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares (if any), which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, the Company classifies its preferred shares in stockholders’ equity. As of December 31, 2013 and 2012, the Company’s preferred shares do not feature any redemption rights within the holders’ control or conditional redemption features not within the Company’s control.  Accordingly, all issuances of preferred stock are presented as a component of consolidated stockholders’ (deficiency) equity.
CONVERTIBLE INSTRUMENTS [Policy Text Block]	'
	Convertible Instruments
	The Company bifurcates conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule when the host instrument is deemed to be conventional as that term is described under applicable U.S. GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.  Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
COMMON STOCK WARRANTS AND OTHER DERIVATIVE FINANCIAL INSTRUMENTS [Policy Text Block]	'
	Common Stock Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock.  The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its private placement transactions (see Note 6). The Company evaluated these warrants to assess their proper classification in the balance sheet as of December 31, 2013 and 2012 using the applicable classification criteria enumerated under U.S. GAAP. The Company determined that the common stock purchase warrants do not contain fixed settlement provisions because the exercise price is subject to adjustment in the event that the Company subsequently issues equity securities or equity linked securities with exercise prices lower than the exercise price in these warrants.
	As such, the Company was required to record the warrants which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period.
RESEARCH AND DEVELOPMENT [Policy Text Block]	'
	Research and Development
	Research and development (“R&D”) expenses are charged to operations as incurred. During the years ended December 31, 2013 and 2012,   and the period from August 4, 2011 (inception) to December 31, 2013, the Company incurred R&D expenses of $158,352, $212,500 and $584,602, respectively.
NET LOSS PER SHARE [Policy Text Block]	'
	Net Loss Per Share
	The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2013 and 2012 excludes potentially dilutive securities because their inclusion would be anti-dilutive. Anti-dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:
		December 31,
		2013		2012
	Warrants to purchase common stock	10,429,900		2,629,000
	Options to purchase common stock	812,500		2,000,000
	Shares issuable upon conversion of convertible notes and accrued interest	953,560		-
	Series A Convertible Preferred Stock	2,457,269		2,200,000
	Series B Convertible Preferred Stock	623,779		309,900
	Totals	15,277,008		7,139,800
SHARE-BASED COMPENSATION [Policy Text Block]	'
	Share-based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and amortized over the respective employment agreements or director service periods. For non-employees, the fair value of the award is measured on the commitment date and generally remeasured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations as if such amounts were paid in cash.
FAIR VALUE OF FINANCIAL INSTRUMENTS [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of cash, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments.
	The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.  ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	ASC 820 describes three levels of inputs that may be used to measure fair value:
	Level 1 — quoted prices in active markets for identical assets or liabilities
	Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	Financial liabilities as of December 31, 2013 and 2012 measured at fair value on a recurring basis are summarized below:
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2013			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	1,248,943		$	—	$	—	$	1,248,943
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2012			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	730,174		$	—	$	—	$	730,174
	The Company determined that the warrants issued in connection with certain Preferred Stock financing transactions and the conversion option and warrants related to certain convertible notes (See Note 5) did not have fixed settlement provisions and are deemed to be derivative financial instruments, since the exercise prices were subject to adjustment based on certain subsequent equity issuances.  Accordingly, the Company was required to record the warrants and conversion option as liabilities and mark to market all such derivatives to fair value each reporting period. Such instruments were classified within Level 3 of the valuation hierarchy.
	Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the warrant liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s Chief Financial Officer, who reports to the Chief Executive Officer, determine its valuation policies and procedures.
	The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.
	Level 3 financial liabilities consist of the warrant liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation.  Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
	The fair value of the Company’s warrant liabilities is estimated using a compound option model that includes characteristics of both a binomial lattice and the Black-Scholes valuation model (see Note 6). Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. Changes in the values of the derivative liabilities are recorded in Change in Fair Value of Warrants on the Company’s consolidated statements of operations. From August 4, 2011 (inception) to December 31, 2013, there were no transfers between levels in the fair value hierarchy.
	The risk-free interest rate is the United States Treasury rate for the day of the grant having a term equal to the contractual life of the warrant. An increase in the risk-free interest rate will increase the fair value and the related change in fair value.  The volatility is a measure of the amount by which the Company’s share price has fluctuated or is expected to fluctuate. Since the Company’s common stock has not been publicly traded for a long period of time, an average of the historic volatility of comparative companies was used.  The dividend yield is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future.
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis for the years ended December 31, 2013 and 2012:
		2013			2012
	Balance - Beginning of period	$	730,174		$	580,000
	Derivative instruments issued		438,375			83,673
	Change in fair value of derivative liabilities		80,394			66,501
	Balance - End of period	$	1,248,943		$	730,174
RECENT ACCOUNTING PRONOUNCEMENT [Policy Text Block]	'
	Recent Accounting Pronouncements
	The Financial Accounting Standards Board (“FASB”) has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.
SUBSEQUENT EVENTS [Policy Text Block]	'
	Subsequent Events
	Management has evaluated subsequent events or transactions occurring through the date on which the consolidated financial statements were issued

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	Anti-dilutive securities excluded from the computation of basic and diluted net loss per share are as follows:
		December 31,
		2013		2012
	Warrants to purchase common stock	10,429,900		2,629,000
	Options to purchase common stock	812,500		2,000,000
	Shares issuable upon conversion of convertible notes and accrued interest	953,560		-
	Series A Convertible Preferred Stock	2,457,269		2,200,000
	Series B Convertible Preferred Stock	623,779		309,900
	Totals	15,277,008		7,139,800
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
	Financial liabilities as of December 31, 2013 and 2012 measured at fair value on a recurring basis are summarized below:
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2013			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	1,248,943		$	—	$	—	$	1,248,943
					Quoted Prices		Significant
					in Active		Other		Significant
					Markets for		Observable		Unobservable
		December 31,			Identical Assets		Inputs		Inputs
		2012			(Level 1)		(Level 2)		(Level 3)
	Derivative liabilities	$	730,174		$	—	$	—	$	730,174
Schedule of Derivative Instruments [Table Text Block]	'
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis for the years ended December 31, 2013 and 2012:
		2013			2012
	Balance - Beginning of period	$	730,174		$	580,000
	Derivative instruments issued		438,375			83,673
	Change in fair value of derivative liabilities		80,394			66,501
	Balance - End of period	$	1,248,943		$	730,174

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The tax effects of temporary differences that give rise to deferred tax assets as of December 31, 2013 and December 31, 2012 are presented below:
		2013		2012
	Deferred Tax Assets:
	Net operating loss carryforward	$	1,247,206	$	941,555
	Stock based compensation		50,500		—
	Total Deferred Tax Asset		1,297,706		941,555
	Valuation allowance		-1,297,706		-941,555
	Deferred Tax Asset, Net of Valuation Allowance	$	—	$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2013 and 2012 is as follows:
		2013		2012
	U.S. federal statutory rate	-34	%	-34	%
	State and local tax, net of federal benefit	-2.4	%	-3.6	%
	Change in fair value of derivative liability and other permanent differences	7.2	%	-3.4	%
	Change in valuation allowance	29.2	%	41	%
	Income tax provision (benefit)	0	%	0	%
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The income tax provision (benefit) for the year ended December 31, 2013 and 2012 consists of the following:
		2013		2012
	Federal
	Current	$	—	$	—
	Deferred		-333,108		-851,406
	State and Local
	Current		-		-
	Deferred		-23,043		-90,149
	Valuation Allowance		356,151		941,155
	Income Tax Provision (Benefit)	$	—	$	—

STOCKHOLDERS_DEFICIENCY_Tables

STOCKHOLDERS' DEFICIENCY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following assumptions were used in estimating the fair value of stock options granted during the years ended December 31, 2013 and 2012:
		2013				2012
	Weighted Average Exercise Price	$	0.37			$	1.62
	Expected Life		2 years				2-5 years
	Volatility		125	%			50	%
	Dividend Yield		0	%			0	%
	Risk-free interest rate		0.30% - 1.62	%			0.41	%
	Weighted Average Grant Date Fair Value of Options Issued	$	0.37			$	1.7
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the Company’s options outstanding and exercisable is presented below:
						Weighted
						Average
				Weighted		Remaining
				Average		Contractual		Aggregate
		Number of		Exercise		Life		Intrinsic
		Shares		Price		(Years)		Value
	Balance – January 1, 2012	-		-		-
	Granted	2,000,000		1.62		5.18
	Exercised	-
	Cancelled	-
	Balance – December 31, 2012	2,000,000		1.62		5.18		$	—
	Granted	75,000		0.37		4.48
	Exercised	-
	Cancelled	1,262,500		1.57		-
	Balance – December 31, 2013	812,500		1.58		3.04		$	—
	Balance – December 31, 2013 (exercisable)	737,500		1.7		2.89		$	—
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]	'
	The following table summarizes the Company’s warrant activity through December 31, 2013:
							Weighted
							Average
				Weighted			Remaining
				Average			Contractual		Aggregate
		Number of		Exercise			Life		Intrinsic
		Shares		Price			(Years)		Value
	Warrants outstanding at January 1, 2012	2,320,000		$	1		2.96
	Granted	309,900		$	1		3.78
	Warrants outstanding at December 31, 2012	2,629,900		$	1		3.06
	Granted	7,800,000		$	1		4.43
	Expired	—			—		—
	Exercised	—			—		—
	Warrants outstanding at December 31, 2013	10,429,900		$	1		4.08		$	—
	Warrants outstanding at December 31, 2013 (exercisable)	10,429,900		$	1		4.08		$	—
Series B Preferred Stock [Member]	'
Stockholders Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair value of these warrants on the issuance date was calculated using a compound option model that includes characteristics of both a binomial lattice and the Black-Scholes formula with the following weighted average assumptions:
	Dividend Yield		0	%
	Volatility		95	%
	Risk-free Interest Rate		0.66-0.72	%
	Expected Lives		4.78 years
	Weighted Average Fair Value per Warrant		0.25	%
	Warrants Issued		309,900
	Aggregate Grant Date Fair Value	$	83,673

GOING_CONCERN_AND_MANAGEMENT_P1

GOING CONCERN AND MANAGEMENT PLANS (Details Textual) (USD $)	5 Months Ended	12 Months Ended		29 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Aug. 03, 2011
Going Concern and Management Plans [Line Items]	'	'	'	'	'
Working Capital Deficiency	'	$1,732,610	'	$1,732,610	'
Net Loss	1,055,724	1,220,202	1,699,466	3,975,392	'
Stockholders' Deficiency	($457,418)	$2,278,626	$875,322	$2,278,626	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,277,008	7,139,800
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,429,900	2,629,000
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	812,500	2,000,000
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	953,560	0
Series A Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,457,269	2,200,000
Series B Convertible Preferred Stocks [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	623,779	309,900

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative liabilities	$1,248,943	$730,174	$580,000
Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative liabilities	0	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative liabilities	0	0	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative liabilities	$1,248,943	$730,174	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Balance - Beginning of period	$730,174	$580,000
Derivative instruments issued	438,375	83,673
Change in fair value of derivative liabilities	80,394	66,501
Balance - End of period	$1,248,943	$730,174

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended		29 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Accounting Policies [Line Items]	'	'	'
Research and development expenses	$158,352	$212,500	$584,602

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Assets:	'	'
Net operating loss carryforward	$1,247,206	$941,555
Stock based compensation	50,500	0
Total Deferred Tax Asset	1,297,706	941,555
Valuation allowance	-1,297,706	-941,555
Deferred Tax Asset, Net of Valuation Allowance	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
U.S. federal statutory rate	-34.00%	-34.00%
State and local tax, net of federal benefit	-2.40%	-3.60%
Change in fair value of derivative liability and other permanent differences	7.20%	-3.40%
Change in valuation allowance	29.20%	41.00%
Income tax provision (benefit)	0.00%	0.00%

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Federal	'	'
Current	$0	$0
Deferred	-333,108	-851,406
State and Local	'	'
Current	0	0
Deferred	-23,043	-90,149
Valuation Allowance	356,151	941,155
Income Tax Provision (Benefit)	$0	$0

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards Expiration Period	'2027	'
Operating Loss Carryforwards Subject To Limitations	$802,671	'
Deferred Tax Assets, Valuation Allowance, Current	356,157	941,155
State and Local Jurisdiction [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards	$3,431,000	$2,298,000

SENIOR_SECURED_CONVERTIBLE_NOT1

SENIOR SECURED CONVERTIBLE NOTES (Details Textual) (USD $)

12 Months Ended

29 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 02, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 20, 2013

Mar. 13, 2013

Mar. 13, 2013

Dec. 31, 2013

Dec. 02, 2013

Mar. 13, 2013

Dec. 31, 2013

Dec. 02, 2013

Mar. 13, 2013

Investor [Member]

Warrant [Member]

Warrant [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Senior Secured Convertible Notes [Member]

Investor [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Investor [Member]

Senior Secured Convertible Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Notes Payable (in dollars)

'

'

'

'

'

'

'

'

$210,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

15.00%

'

'

'

15.00%

15.00%

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in dollars per share)

'

'

'

'

$1

'

'

'

$1.50

$1.50

$1

'

'

'

'

'

Debt Instrument, Frequency of Periodic Payment

'

'

'

'

'24 Months

'

'

'

'

'24 Months

'

'

'

'

'

'

Exercise Price of Warrants Issued (in dollars per share)

'

'

'

'

'

'

$1

$1.50

'

'

'

'

$1.50

'

'

'

Debt Instrument, Unamortized Discount (in dollars)

334,209

'

334,209

484,925

'

'

'

'

'

'

'

438,375

'

430,500

46,550

'

Fair Value of Conversion Option (in dollars)

7,875

0

7,875

'

'

'

'

'

'

'

7,875

'

'

'

'

'

Amortization of Debt Discount (Premium) (in dollars)

150,716

0

150,716

'

'

'

'

'

'

'

150,716

'

'

'

'

'

Debt Instrument, Annual Principal Payment

'

'

'

'

'

'

'

525,000

'

'

'

'

'

'

'

'

Warrant Issued to Purchase Common Stock (in shares)

'

'

'

'

'

'

450,000

5,250,000

'

'

'

'

1,400,000

'

'

'

Sale Of Additional Notes

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued (in shares)

16,344,728

16,225,000

16,344,728

'

'

'

'

'

'

'

'

'

1,050,000

'

'

700,000

Warrant Issuance Costs (in dollars)

'

'

'

'

'

35,000

'

'

'

'

'

'

'

'

'

'

Common Stock Invested Under Senior Secured Convertible Note Agreement (in dollars)

'

'

'

'

'

'

'

'

'

'

'

'

105,000

'

'

'

Debt Instrument, Unamortized Discount (Premium), Net, Total

'

'

'

'

'

'

'

'

'

'

484,925

'

'

'

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

'

'

'

$885,000

'

$150,000

'

'

STOCKHOLDERS_DEFICIENCY_Detail

STOCKHOLDERS' DEFICIENCY (Details) (Series B Preferred Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Series B Preferred Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumption and Methodology [Line Items]	'	'
Dividend Yield	0.00%	'
Volatility	95.00%	'
Risk-free Interest Rate - Minimum	0.66%	'
Risk-free Interest Rate - Maximum	0.72%	'
Expected Lives	'4 years 9 months 11 days	'
Weighted Average Fair Value per Warrant	0.25%	'
Warrants Issued	309,900	309,900
Aggregate Grant Date Fair Value	$83,673	'

STOCKHOLDERS_DEFICIENCY_Detail1

STOCKHOLDERS' DEFICIENCY (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
				Stock Option [Member]	Stock Option [Member]	Stock Option [Member]	Stock Option [Member]	Stock Option [Member]	Stock Option [Member]
						Maximum [Member]	Maximum [Member]	Minimum [Member]	Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumption and Methodology [Line Items]	'	'	'	'	'	'	'	'	'
Weighted Average Exercise Price	$1.58	$1.62	$0	$0.37	$1.62	'	'	'	'
Expected Life	'	'	'	'2 years	'	'	'5 years	'	'2 years
Volatility	'	'	'	125.00%	50.00%	'	'	'	'
Dividend Yield	'	'	'	0.00%	0.00%	'	'	'	'
Risk-free interest rate	'	'	'	'	0.41%	1.62%	'	0.30%	'
Weighted Average Grant Date Fair Value of Options Issued	'	'	'	$0.37	$1.70	'	'	'	'

STOCKHOLDERS_DEFICIENCY_Detail2

STOCKHOLDERS' DEFICIENCY (Details 2) (USD $)	1 Months Ended		5 Months Ended	12 Months Ended
	Jun. 30, 2012	Apr. 30, 2012	Aug. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Number of Shares, Beginning balance	'	'	'	2,000,000	0	'
Number of Shares, Granted	50,000	100,000	'	75,000	2,000,000	'
Number of Shares, Exercised	'	'	'	0	0	'
Number of Shares, Cancelled	'	'	'	1,262,500	0	'
Number of Shares, Ending balance	'	'	'	812,500	2,000,000	0
Number of Shares, Balance - (exercisable)	'	'	'	737,500	'	'
Weighted Average Exercise Price, Beginning balance	'	'	'	$1.62	$0	'
Weighted Average Exercise Price, Granted	'	'	'	$0.37	$1.62	'
Weighted Average Exercise Price, Cancelled	'	'	'	$1.57	'	'
Weighted Average Exercise Price, Ending balance	'	'	'	$1.58	$1.62	$0
Weighted Average Exercise Price, Balance - (exercisable)	$1.97	$2.30	'	$1.70	'	'
Weighted Average Remaining Contractual Life, Outstanding	'	'	'5 years	'3 years 14 days	'5 years 2 months 5 days	'0 years
Weighted Average Remaining Contractual Life, Granted	'	'	'	'4 years 5 months 23 days	'5 years 2 months 5 days	'
Weighted Average Remaining Contractual Life, Cancelled	'	'	'	'0 years	'	'
Weighted Average Remaining Contractual Life, Exercisable	'	'	'	'2 years 10 months 20 days	'	'
Aggregate Intrinsic Value - Balance	'	'	'	$0	$0	'
Aggregate Intrinsic Value - (exercisable)	'	'	'	$0	'	'

STOCKHOLDERS_DEFICIENCY_Detail3

STOCKHOLDERS' DEFICIENCY (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrant Activity [Line Items]	'	'	'
Number of Shares, Warrants outstanding - Beginning balance	2,629,900	2,320,000	'
Number of Shares, Warrants - Granted	7,800,000	309,900	'
Number of Shares, Warrants - Expired	0	'	'
Number of Shares, Warrants - Exercised	0	'	'
Number of Shares, Warrants outstanding - exercisable	10,429,900	'	'
Number of Shares, Warrants outstanding - Ending balance	10,429,900	2,629,900	2,320,000
Weighted Average Exercise Price, Warrants outstanding - Beginning balance	$1	$1	'
Weighted Average Exercise Price, Warrants - Granted	$1	$1	'
Weighted Average Exercise Price, Warrants - Expired	$0	'	'
Weighted Average Exercise Price, Warrants - Exercised	$0	'	'
Weighted Average Exercise Price, Warrants outstanding - Ending balance	$1	$1	$1
Weighted Average Exercise Price, Warrants outstanding - exercisable	$1	'	'
Weighted Average Remaining Contractual Life, Warrants outstanding	'4 years 29 days	'3 years 22 days	'2 years 11 months 16 days
Weighted Average Remaining Contractual Term, Warrants - Granted	'4 years 5 months 5 days	'3 years 9 months 11 days	'
Weighted Average Remaining Contractual Term, Warrants - Exercised	'0 years	'	'
Weighted Average Remaining Contractual Term, Warrants outstanding - exercisable	'4 years 29 days	'	'
Aggregate Intrinsic Value, Warrants outstanding - Balance	$0	'	'
Aggregate Intrinsic Value, Warrants outstanding - exercisable	$0	'	'

STOCKHOLDERS_DEFICIENCY_Detail4

STOCKHOLDERS' DEFICIENCY (Details Textual) (USD $)

1 Months Ended

5 Months Ended

12 Months Ended

29 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Jul. 31, 2013

Feb. 12, 2013

Jun. 30, 2012

Apr. 30, 2012

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Mar. 13, 2013

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2012

Aug. 31, 2012

Jun. 30, 2012

Apr. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 31, 2012

Jun. 30, 2012

Apr. 30, 2012

Aug. 31, 2012

Jun. 30, 2012

Apr. 30, 2012

Oct. 31, 2012

Oct. 31, 2012

Oct. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Aug. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 10, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2013

Senior Secured Convertible Note [Member]

Senior Secured Convertible Note [Member]

Employee Stock Option [Member]

Common Stock [Member]

Common Stock [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

President, Chief Executive Officer and Chief Financial Officer [Member]

President, Chief Executive Officer and Chief Financial Officer [Member]

President, Chief Executive Officer and Chief Financial Officer [Member]

Advisory Board [Member]

Advisory Board [Member]

Advisory Board [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Minimum [Member]

Maximum [Member]

Vested On Date Of Grant [Member]

Vested On Date Of Grant [Member]

Vested On Date Of Grant [Member]

First Anniversary Date Of Grant [Member]

First Anniversary Date Of Grant [Member]

First Anniversary Date Of Grant [Member]

Vested On Date Of Grant [Member]

First Anniversary Date Of Grant [Member]

Vested On Date Of Grant [Member]

First Anniversary Date Of Grant [Member]

Preferred Stock [Member]

Third Party [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

'

'

200,000,000

200,000,000

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share

'

'

'

'

'

$0.00

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

'

'

'

5,000,000

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

50,000

'

'

'

3,500,000

3,500,000

'

Preferred Stock, Par or Stated Value Per Share

'

'

'

'

'

$0.00

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$175

$175

'

'

'

$1

$1

'

Stock Issued During Period Shares Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,099

'

'

'

'

Dividends, Preferred Stock, Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$81,454

$14,620

'

'

'

$358,056

$183,812

'

Debt Conversion, Converted Instrument, Warrants or Options Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

309,900

309,900

'

'

'

'

'

'

Stock Issued During Period Private Placement Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.62

'

'

'

'

'

'

Proceeds From Issuance Of Preferred Stock and Preference Stock

'

'

'

'

'

0

514,103

'

1,714,104

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

542,325

'

'

'

'

'

'

Stockholders Equity Note, Stock Split

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Upon the third anniversary of the date of issuance, each share of Series B Preferred Stock still outstanding, unless there is an event of default (as defined), will automatically convert into shares of Common Stock at the then effective conversion ratio.

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

8.00%

'

'

Preferred Stock, Liquidation Preference, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

623,779

556,945

'

'

'

2,457,269

2,383,812

'

Payments of Stock Issuance Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,222

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

10,000

'

'

'

'

'

'

'

'

'

'

10,000

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

5,800

'

'

'

5,800

20,650

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

'

'

'

16,344,728

16,225,000

'

16,344,728

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

109,728

Preferred Stock Convertible Into Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

Common Stock Dividends, Shares

9,728

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

50,000

100,000

'

75,000

2,000,000

'

'

'

'

'

'

'

50,000

'

'

75,000

'

'

'

'

'

'

'

'

1,700,000

'

'

100,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price

'

'

$1.97

$2.30

'

$1.70

'

'

$1.70

'

'

'

'

'

$1.88

'

'

'

$0.11

$0.52

'

'

'

'

'

'

$1.55

'

'

$1.82

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

25,000

50,000

25,000

25,000

50,000

'

250,000

250,000

'

50,000

50,000

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value

'

'

'

'

'

5,310

'

'

'

'

'

'

'

'

1,022

905

1,190

'

'

'

'

'

'

'

'

'

76,392

'

'

7,587

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

'

'

'

'

'

1,550

'

'

1,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Options Forfeiture

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'

'

'

'

'5 years

'3 years 14 days

'5 years 2 months 5 days

'0 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options Issued To Purchase Common Stock

'

'

'

'

'

'

'

'

'

'

'

1,262,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Grant Date Fair Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,673

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

20,650

5,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

81,454

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit

'

'

'

'

'

$0.11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit

'

'

'

'

'

$2.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Aggregate Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,673

'

'

'

'

'

'

'

Preferred Stock Conversion Price, Initial

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.75

'

'

'

'

'

Preferred Stock Conversion Price, Reduced

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

Number of Common Stock Shares to be Issued for Each Share of Preferred Stock Excluding Accrued Dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

542,325

'

'

'

'

'

'

'

Number of Common Stock Shares to be Issued for Accrued Dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

81,454

'

'

'

'

'

'

'

Number of Common Stock Shares to be Issued for Each Share of Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

623,779

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

$1

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

'

'

'

'

'

1,262,500

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

'

'

'

'

'

$5,626

$133,295

'

$138,920

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)

1 Months Ended

12 Months Ended

29 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Feb. 12, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2012

Mar. 31, 2013

Nov. 06, 2012

Apr. 24, 2013

Apr. 30, 2013

Dec. 31, 2012

25-May-12

31-May-12

Chief Executive Officer and Director [Member]

David W Todhunter [Member]

Dr. Del Vecchio [Member]

West Palm Beach [Member]

West Palm Beach [Member]

West Palm Beach [Member]

Rome and Italy [Member]

Rome and Italy [Member]

Other Commitments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

'

$29,344

$9,180

$38,524

'

'

'

'

'

'

'

'

Repayments of Debt and Capital Lease Obligations

'

'

'

'

21,513

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Share-based Compensation, Gross

'

'

'

'

40,000

'

'

'

'

'

'

'

Stock Issued During Period, Value, Share-based Compensation, Gross

'

'

'

'

23,600

'

'

'

'

'

'

'

Officers Compensation

'

'

'

'

'

126,000

'

'

'

'

'

'

Percentage Of Cash Bonus

'

'

'

'

'

50.00%

'

'

'

'

'

'

Agreement Expiry Date

'

'

'

'

'

31-Dec-15

'

'

'

'

'

'

Consulting Agreement Fees Periodic Payment

'

'

'

'

'

'

7,750

'

'

'

'

'

Description of Lessor Leasing Arrangements, Operating Leases

'

'

'

'

'

'

'

'On April 24, 2013, the Company entered into a commercial lease agreement in West Palm Beach, Florida under a one year operating lease that commenced on June 1, 2013 at the rate of $1,020 per month

'

'

'On May 25, 2012, the Company entered into a commercial lease agreement in Rome, Italy under a one-year operating lease that commenced on June 1, 2012 at the rate of approximately $1,300 per month

'

Stock Issued During Period, Shares, Issued for Services

10,000

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

5,800

5,800

20,650

'

'

'

'

'

'

'

'

'

Monthly Commercial Lease Rent

'

'

'

'

'

'

'

'

1,020

975

'

1,300

Operating Leases, Future Minimum Payments Due, Total

'

$10,300

'

$10,300

'

'

'

'

'

'

'

'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member], USD $)	2 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended				12 Months Ended
	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Feb. 12, 2014	Feb. 12, 2014	Feb. 12, 2014	Dec. 31, 2013
	Steven Elliott [Member]	Steven Elliott [Member]	Consultant [Member]	Consultant [Member]	Consummation of Debt or Equity Financing [Member]	First Anniversary Date Of Grant [Member]	Thirty Six Months Following First Anniversary Date Of Grant [Member]	Securities Purchase Agreement [Member]
					Steven Elliott [Member]	Steven Elliott [Member]	Steven Elliott [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Agreement Expiry Date	'	12-Feb-18	'	'	'	'	'	'
Officers Compensation	'	$240,000	'	'	'	'	'	'
Percentage Of Cash Bonus	'	50.00%	'	'	'	'	'	'
Consulting Agreement Fees Periodic Payment	'	'	20,000	240,000	'	'	'	'
Proceeds From Notes Payable	'	'	'	'	'	'	'	100,000
Warrant Issued To Purchase Common Stock	'	'	'	'	'	'	'	600,000
Exercise Price Of Warrants Issued	'	'	'	'	'	'	'	$1
Maximum Value of Options to be Vested	'	'	'	'	$3,000,000	'	'	'
Options To Be Vested per Month	'	'	'	'	'	'	46,875	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	3,000,000	'	'	'	'	'	'	'
Investment Options, Exercise Price	$0.50	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	'	'	'	'	750,000	562,500	1,687,500	'